NO20080125L - 2,6-kinolinylderivater, fremgangsmater for fremstilling derav og deres anvendelse som medikament - Google Patents

2,6-kinolinylderivater, fremgangsmater for fremstilling derav og deres anvendelse som medikament

Info

Publication number
NO20080125L
NO20080125L NO20080125A NO20080125A NO20080125L NO 20080125 L NO20080125 L NO 20080125L NO 20080125 A NO20080125 A NO 20080125A NO 20080125 A NO20080125 A NO 20080125A NO 20080125 L NO20080125 L NO 20080125L
Authority
NO
Norway
Prior art keywords
processes
preparation
medicament
quinolinyl derivatives
diseases including
Prior art date
Application number
NO20080125A
Other languages
English (en)
Inventor
Benjamin Perry
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0511781A external-priority patent/GB0511781D0/en
Priority claimed from GB0600213A external-priority patent/GB0600213D0/en
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Publication of NO20080125L publication Critical patent/NO20080125L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Foreliggende oppfinnelse angår 2,6-kinolinylderivater, fremgangsmåter for fremstilling av disse, farma- søytiske preparater inneholdende dem og deres anvendelse som farmasøytiske midler. Eksempelvis er forbindelsene ifølge oppflnnelsen anvendbare for behandling av astma, allergisk rhinitt, sinusitt, konjunktivitt, matallergi, inflammatoriske hudsykdommer innbefattende dermatitt, psoriasis, urticaria, pruritus og eksem, reumatoid artritt, inflammatoriske tarmsykdommer innbefattende Crohns sykdom og ulcerøs kolitt, multippel sklerose og andre autoimmune sykdommer, og aterosklerose.
NO20080125A 2005-06-09 2008-01-08 2,6-kinolinylderivater, fremgangsmater for fremstilling derav og deres anvendelse som medikament NO20080125L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0511781A GB0511781D0 (en) 2005-06-09 2005-06-09 2,6-quinolinyl derivatives, processes for preparing them and their uses
US20615805A 2005-08-18 2005-08-18
GB0600213A GB0600213D0 (en) 2006-01-06 2006-01-06 2,6-quinolinyl derivatives, processes for preparing them and their uses
PCT/EP2006/004811 WO2006131200A1 (en) 2005-06-09 2006-05-22 2,6 quinolinyl derivatives, processes for preparing them and their use as medicament

Publications (1)

Publication Number Publication Date
NO20080125L true NO20080125L (no) 2008-01-08

Family

ID=36968449

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20080125A NO20080125L (no) 2005-06-09 2008-01-08 2,6-kinolinylderivater, fremgangsmater for fremstilling derav og deres anvendelse som medikament

Country Status (19)

Country Link
US (1) US7732614B2 (no)
EP (1) EP1902045B1 (no)
JP (1) JP2008542407A (no)
KR (1) KR20080021085A (no)
AR (1) AR054129A1 (no)
AT (1) ATE496041T1 (no)
AU (1) AU2006254772B2 (no)
BR (1) BRPI0611243A2 (no)
CA (1) CA2610800A1 (no)
DE (1) DE602006019731D1 (no)
EA (1) EA013080B1 (no)
IL (1) IL187235A0 (no)
MX (1) MX2007014721A (no)
MY (1) MY140739A (no)
NO (1) NO20080125L (no)
NZ (1) NZ563739A (no)
PE (1) PE20070081A1 (no)
TW (1) TW200716605A (no)
WO (1) WO2006131200A1 (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL373763A1 (en) 2002-04-30 2005-09-19 Ucb, S.A. 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as vla-4 inhibitors
CA2478458A1 (en) * 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
AU2005306399B2 (en) * 2004-11-19 2012-02-09 Biogen Ma Inc. Treatment for multiple sclerosis
CA2610800A1 (en) 2005-06-09 2006-12-14 Ucb Pharma, S.A. 2,6 quinolinyl derivatives, processes for preparing them and their use as medicament
WO2008125215A1 (en) * 2007-04-12 2008-10-23 Ucb Pharma, S.A. Bicyclic and heterobicyclic derivatives, processes for preparing them and their uses
CA2758548A1 (en) * 2009-04-17 2010-10-21 Biogen Idec Ma Inc. Compositions and methods to treat acute myelogenous leukemia
HUE035098T2 (en) 2010-04-16 2018-05-02 Biogen Ma Inc Anti-VLA4 Antibodies
MY160723A (en) * 2013-12-30 2017-03-15 Univ Putra Malaysia An anticoagulant
USD812958S1 (en) 2016-06-08 2018-03-20 Samsung Electronics Co., Ltd. Cooktop
WO2019200202A1 (en) 2018-04-12 2019-10-17 Morphic Therapeutic, Inc. Antagonists of human integrin (alpha4)(beta7)
WO2020092401A1 (en) * 2018-10-30 2020-05-07 Gilead Sciences, Inc. COMPOUNDS FOR INHIBITION OF ALPHA 4β7 INTEGRIN
CA3114240C (en) 2018-10-30 2023-09-05 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
US11224600B2 (en) 2018-10-30 2022-01-18 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
EP3873884A1 (en) * 2018-10-30 2021-09-08 Gilead Sciences, Inc. Quinoline derivatives as alpha4beta7 integrin inhibitors
JP7491996B2 (ja) 2019-08-14 2024-05-28 ギリアード サイエンシーズ， インコーポレイテッド α４β７インテグリンの阻害のための化合物
KR20220102669A (ko) 2019-10-16 2022-07-20 모픽 테라퓨틱, 인코포레이티드 인간 인테그린 α4β7의 억제

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996018606A1 (fr) 1994-12-14 1996-06-20 Santen Pharmaceutical Co., Ltd. Nouveaux derives 1,3-dialkyluree
HU229362B1 (en) 1997-08-22 2013-11-28 Hoffmann La Roche N-alkanoylphenylalanine derivatives
EP1114028B1 (en) 1998-08-26 2006-11-29 Aventis Pharma Limited Aza-bicycles which modulate the inhibition of cell adhesion
MXPA01010916A (es) 1999-04-28 2002-06-21 Reddy Research Foundation Heterociclos biciclicos sustituidos, procedimiento para su preparacion y su uso como agentes contra la obesidad y como agentes hipocolesterolemicos.
MY129000A (en) 2000-08-31 2007-03-30 Tanabe Seiyaku Co INHIBITORS OF a4 MEDIATED CELL ADHESION
MY140707A (en) 2002-02-28 2010-01-15 Mitsubishi Tanabe Pharma Corp Process for preparing a phenylalanine derivative and intermediates thereof
PL373763A1 (en) * 2002-04-30 2005-09-19 Ucb, S.A. 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as vla-4 inhibitors
US7153870B2 (en) * 2003-07-25 2006-12-26 Pfizer Inc. Nicotinamide derivatives useful as PDE4 inhibitors
GB0329584D0 (en) 2003-12-20 2004-01-28 Tanabe Seiyaku Co Novel compounds
CA2610800A1 (en) 2005-06-09 2006-12-14 Ucb Pharma, S.A. 2,6 quinolinyl derivatives, processes for preparing them and their use as medicament

Also Published As

Publication number Publication date
JP2008542407A (ja) 2008-11-27
AR054129A1 (es) 2007-06-06
KR20080021085A (ko) 2008-03-06
PE20070081A1 (es) 2007-02-15
IL187235A0 (en) 2008-02-09
EA200702589A1 (ru) 2008-06-30
CA2610800A1 (en) 2006-12-14
EA013080B1 (ru) 2010-02-26
WO2006131200A1 (en) 2006-12-14
NZ563739A (en) 2009-12-24
MY140739A (en) 2010-01-15
EP1902045B1 (en) 2011-01-19
MX2007014721A (es) 2008-02-14
TW200716605A (en) 2007-05-01
DE602006019731D1 (de) 2011-03-03
ATE496041T1 (de) 2011-02-15
US7732614B2 (en) 2010-06-08
BRPI0611243A2 (pt) 2010-08-24
US20070004775A1 (en) 2007-01-04
AU2006254772A1 (en) 2006-12-14
EP1902045A1 (en) 2008-03-26
AU2006254772B2 (en) 2011-06-02

Similar Documents

Publication Publication Date Title
NO20080125L (no) 2,6-kinolinylderivater, fremgangsmater for fremstilling derav og deres anvendelse som medikament
SG155943A1 (en) Pyridazin-3(2h)-one derivatives and their use as pde4 inhibitors
CL43596B (es) Compuestos derivados de pirimidina; composicion farmaceutica; y su uso para tratar o prevenir un trastorno o enfermedad relacionado con la actividad de crth2, tales como asma, rinitis alergica, dermatitis, atopica y conjuntivitis alergica.
ME01515B (me) PIRIMIDINSKI DERIVATI ZA TRETMAN ASTME, HOBP, ALERGIJSKOG RINITISA, ALERGIJSKOG KONJUNKTIVITISA, ATOPIČNOG DERMATITISA, RAKA, HEPATITISA B, HEPATITISA C, HIV-a, HPV-a, BAKTERIJSKIH INFEKCIJA I DERMATOZE
NO20081211L (no) Xantinderivater som selektive HM74A agonister
HRP20050318A2 (en) Pyrimidinone derivatives as therapeutic agents against acute and chronic inflamatory, ischaemic and remodelling processes
NO20064659L (no) Nye kvarterniserte quinuklidin-estere
NO20072784L (no) Pyridenkarboksamidderivater for anvendelse som anticancer midler
NO20045234L (no) 2,6-kinolinyl- og 2,6-naftylderivater, fremgangsmate for fremstilling av disse, og anvendelse av disse som VLA-4-inhibitorer
NO20083427L (no) Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse
ATE479678T1 (de) Benzoimidazol-2-yl pyridine als modulatoren des histamin-h4-rezeptors
NO20083919L (no) Pyridin- og pyrimidinderivater som mGluR2-antagonister
MX2009008787A (es) Moduladores 2-aminopirimidina del receptor de histamina h4.
NO341523B1 (no) Benzoimidazol-2-ylpyrimidiner og -pyraziner som modulatorer av histamin H4-reseptoren, farmasøytisk sammensetning samt anvendelse
WO2005021515A3 (en) Inhibitors of phosphodiesterase type-iv
ATE457311T1 (de) Als inhibitoren von proteinkinasen geeignete aminopyridine und aminopyrimidine
NO20052076L (no) Fuserte azol-pyrimidinderivater.
BR112013029862A2 (pt) derivados de piridin-2 (1h)-ona úteis como medicamentos para o tratamento de distúrbios mieloproliferativos, rejeição a transplante, doenças imunomediadas e inflamatórias
NO20090268L (no) Benzofuro- and benzothienopyrimidine modulators of the histamine H4 receptor
NO20083358L (no) Piperasinyl derivater som modulatorer for kjemokine reseptor aktivitet
NO20082684L (no) F-, G-, H-, I- og K-krystallformer av imatinibmesylat
NZ594854A (en) Low-molecular polysulfated hyaluronic acid derivative and medicine containing same
NO20090266L (no) Piperazinylderivater anvendelige i behandlingen av GPR38 receptormedierte sykdommer
WO2006085212A3 (en) Condensed isoxaline derivatives as inhibitors of phosphodiesterase type-iv
MX2009008425A (es) Derivados de 1-bencensulfonil-1h-indol como inhibidores de la actividad de ccr9.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application